New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

January 2005

January 7

Abraxane (paclitaxel protein-bound) for Injectable Suspension

Date of Approval: January 7, 2005
Company: American Pharmaceutical Partners, Inc. / American Bioscience, Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer

Abraxane (paclitaxel protein-bound) is an albumin-bound form of the antineoplastic agent paclitaxel indicated for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.

Abraxane (paclitaxel protein-bound) FDA Approval History

January 12

ThyroShield (potassium iodide) Oral Solution

Date of Approval: January 12, 2005
Company: Fleming & Company
Treatment for: Radiation Emergency

ThyroShield (potassium iodide) is used to protect the thyroid gland from the effects of radiation from inhaled or swallowed radioactive iodine.

ThyroShield (potassium iodide) FDA Approval History

January 14

Menactra (meningococcal conjugate vaccine)

Date of Approval: January 14, 2005
Company: Sanofi Pasteur
Treatment for: Meningococcal Meningitis Prophylaxis

Menactra (meningococcal conjugate vaccine) is a quadrivalent conjugate vaccine indicated for the prevention of meningococcal disease.

Menactra (meningococcal conjugate vaccine) FDA Approval History

January 19

Niravam (alprazolam) Orally Disintegrating Tablets

Date of Approval: January 19, 2005
Company: Schwarz Pharma AG
Treatment for: Anxiety, Panic Disorder

Niravam (alprazolam) is an orally disintegrating benzodiazepine indicated for the short-term relief of anxiety and panic attacks.

Niravam (alprazolam) FDA Approval History

January 31

Eloxatin (oxaliplatin)

New Formulation Approved: January 31, 2005

January 31

Nascobal (cyanocobalamin)

New Formulation Approved: January 31, 2005

Nascobal (cyanocobalamin) FDA Approval History

April 25

Menactra (meningococcal conjugate vaccine)

Patient Population Altered: April 22, 2011

Menactra (meningococcal conjugate vaccine) FDA Approval History

October 12

Abraxane (paclitaxel protein-bound)

New Indication Approved: October 11, 2012

Abraxane (paclitaxel protein-bound) FDA Approval History

September 6

Abraxane (paclitaxel protein-bound)

New Indication Approved: September 6, 2013

Abraxane (paclitaxel protein-bound) FDA Approval History

Hide
(web4)